Antibodies with chimeric constant domains reduce effector functions

The USPTO has published a patent application (US20260085117A1) detailing antibodies with chimeric constant domains designed to reduce effector functions. The application, filed on November 24, 2025, describes recombinant polypeptides and methods for their production.

Patent Application: Antibody Heavy Chain Regions Reduce Fc Gamma Receptor Binding

The USPTO has published a patent application (US20260085116A1) detailing antibody heavy chain constant regions modified to reduce binding to Fc gamma receptors. This modification, achieved through specific residue replacements or deletions in the hinge region, aims to decrease effector functions in antibodies and Fc fusion proteins.

CD3 Binding Antibodies Patent Application Inventors Listed

The USPTO has published a new patent application, US20260085115A1, related to CD3 binding antibodies. The application, filed on June 2, 2025, lists inventors Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, and Duy Pham.

Anti-GPRC5D Antibody for Cancer Treatment

The USPTO has published a patent application (US20260085114A1) filed by Kyinno Biotechnology Co., Ltd. The application describes an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or fragment thereof for the treatment of tumors or cancers. It also details a bispecific antibody targeting GPRC5D and CD3.

N-Phenyl-Pyrazolo[1,5-A]pyridine Derivatives Treat Urticaria

The European Patent Office has published patent application EP4626884A1 concerning N-Phenyl-Pyrazolo[1,5-A]pyridine derivatives as inhibitors for treating urticaria. The application lists Blueprint Medicines Corporation as the applicant.

Janssen Pharmaceutica NV Patent EP4626885A1 for Bicyclic Compounds

The European Patent Office has published patent application EP4626885A1 for Janssen Pharmaceutica NV, detailing bicyclic compounds. The patent covers cyclobutyl substituted bicyclic compounds with potential applications in treating certain cancers.

Patent Application: Fused Azole Derivatives as Diacylglyceride Inhibitors

The European Patent Office has published patent application EP4626881A1 for fused azole derivatives developed by Merck Sharp & Dohme LLC. These compounds are identified as novel diacylglyceride O-acyltransferase 2 inhibitors, potentially impacting treatments for metabolic and cardiovascular diseases.

EPO Patent EP4512801A1 for 3,4-Dihydroquinolin-2(1H)-one Compound

The European Patent Office has published patent application EP4512801A1 for a 3,4-dihydroquinolin-2(1H)-one compound developed by Kissei Pharmaceutical Co., Ltd. The patent application was published on March 11, 2026, and covers various designated states within the European Union.

Patent EP4626864A1: Diamide Activators by Protego Biopharma

The European Patent Office has published patent application EP4626864A1, titled 'Diamide Activators', filed by Protego Biopharma, Inc. The patent covers novel chemical compounds intended for use as IRE1/XBP1s activators.

Pyridine derivatives as protein kinase inhibitors patent publication

The European Patent Office has published patent application EP4622971A1 concerning pyridine derivatives as protein kinase inhibitors, filed by Hirundo Biosciences. This publication details novel chemical compounds and their potential therapeutic applications.